BioCentury
ARTICLE | Clinical News

Affimed reports Phase Ib data of AFM13 plus Keytruda for Hodgkin's lymphoma

February 9, 2018 6:44 PM UTC

Affimed N.V. (NASDAQ:AFMD) reported data from nine evaluable patients with relapsed or refractory Hodgkin's lymphoma in a Phase Ib trial showing that 7 mg/kg IV AFM13 plus anti-PD-1 mAb Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) led to an objective response rate (ORR) of 89%, including four complete metabolic responses and four partial metabolic responses, plus one case of stable disease. The combination was well tolerated.

The open-label trial's primary endpoint is dose-limiting toxicities (DLTs). Secondary endpoints include safety and ORR...